Showing 1831-1840 of 5631 results for "".
- Eyenovia Announces Poster Presentation at ASCRS 2022https://modernod.com/news/eyenovia-announces-poster-presentation-at-ascrs-2022/2480776/Eyenovia announced that the company will present an ePoster at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, which is being held April 23-26 in Washington, D.C. Details of the ePoster presentation are as follows: <
- Brim Biotechnology and Ora Announce Partnership to Accelerate Development of Regenerative Peptide Therapy, BRM421, for Dry Eyehttps://modernod.com/news/brim-biotechnology-and-ora-inc-announce-new-partnership-to-accelerate-development-of-regenerative-peptide-therapy-brm421-for-dry-eye-syndrome/2480867/Brim Biotechnology announces it has entered into a new strategic partnership with Ora Inc. for the late-stage clinical development of lead drug candidate, BRM421, for dry eye syndrome (DES). Brim intends to initiate phase 3 clinical studies with Ora’s support later this year.
- AAO: Home OCT Device Improves Care for AMD Patients, Reduces Costs and Burdenhttps://modernod.com/news/aao-home-oct-device-improves-care-for-amd-patients-reduces-costs-and-burden/2482499/A newly approved home-based OCT device developed by Notel Vision is allowing patients to monitor their own eye health between appointments, providing physicians with crucial data without requiring in-office visits, according to an AAO news release. A study presented today at AAO 2024 suggest
- Corza Medical Opens Ophthalmology Center of Technology and Innovationhttps://modernod.com/news/corza-medical-opens-ophthalmology-center-of-technology-and-innovation/2481992/Corza Medical announced the opening of its new Ophthalmology Center of Technology and Innovation in St. Louis. The state-of-the-art facility is aimed at advancing the development of next-generation devices for ophthalmic surgeries and other eye treatments. With an approximate footp
- Atsena Therapeutics Announces Opening of New Office and Laboratory Space in North Carolina’s Research Trianglehttps://modernod.com/news/atsena-therapeutics-announces-opening-of-new-office-and-laboratory-space-in-north-carolinas-research-triangle/2480994/Atsena Therapeutics announced the opening of its new office and laboratory in the Alexandria Center for Advanced Technologies–Research Triangle. The occasion was celebrated during a ribbon-cutting ceremony yesterday. The new state-of-the-art facility consist
- Alimera Exhibits Continued Growth and Expansion With New Branding and Office Relocationhttps://modernod.com/news/alimera-exhibits-continued-growth-and-expansion-with-new-branding-and-office-relocation/2480750/Alimera Sciences announced that the company has launched new corporate branding and moved its global headquarters to a new, state-of-the-art facility. Alimera refreshed its corporate brand for the first time in the company’s two-decade history to better represent its current
- American Academy of Optometry Foundation Announces Award Recipientshttps://modernod.com/news/american-academy-of-optometry-foundation-announces-award-recipients/2479474/Jonathan D. Lam, MD, OD, was this year’s recipient of the Hopkins Comprehensive Eye Care Award. Dr. Lam is a primary care/ocular disease resident at the Chinle Comprehensive Health Care Facility in Chinle, Arizona. Douglas W. Hopkins, OD, FAAO, was a leader within the Primary Care Section
- Johnson & Johnson Takes Charge of Emergent COVID-19 Vaccine Manufacturing Sitehttps://modernod.com/news/johnson-johnson-takes-charge-of-emergent-covid-19-vaccine-manufacturing-site/2479052/The US Department of Health & Human Services (HHS) has put Johnson & Johnson in charge of the Emergent BioSolutions’ Bayview facility in Baltimore, which ruined around 15 million doses of its COVID-19 vaccine Ad26.COV2.S. Johnson & Johnson said it was “assuming full
- Lilly’s Bamlanivimab Cuts Risk of COVID-19 By Up to 80% at Nursing Homeshttps://modernod.com/news/lillys-bamlanivimab-cuts-risk-of-covid-19-by-up-to-80-at-nursing-homes/2478788/Eli Lilly announced Thursday that in a phase 3 study, bamlanivimab was shown to significantly reduce the risk of contracting symptomatic COVID-19 among residents and staff of long-term care facilities. The findings from the BLAZE-2 COVID-19 prevention trial suggest the risk was decreased by up to
- BioNTech Snaps Up Novartis’ German Site to Expand Coronavirus Vaccine Outputhttps://modernod.com/news/biontech-snaps-up-novartis-german-site-to-expand-coronavirus-vaccine-output/2478296/BioNTech announced that it signed a share purchase agreement to acquire Novartis’ manufacturing facility in Marburg, Germany, a move it says will bolster its COVID-19 vaccine production capacity by up to 750 million doses per year, or over 60 million doses per month. BioNTech, whose Pfizer-